Showing 2131-2140 of 5623 results for "".
- BVI Medical Raises $1 Billion to Fuel Global Growthhttps://modernod.com/news/bvi-medical-raises-1-billion-to-fuel-global-growth/2482692/BVI Medical has completed a $1 billion strategic capital raise in partnership with asset management firm TPG. According to BVI, the investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, aims to strengthen the company&
- Nicox Announces New Data from the NCX 470 Mont Blanc Trial, Provides Development Updateshttps://modernod.com/news/nicox-announces-new-data-from-the-ncx-470-mont-blanc-trial-provides-development-updates/2482684/Nicox, an international ophthalmology company, shared new data on their intraocular pressure (IOP)-lowering medication NCX 470 at the 2025 American Glaucoma Society (AGS) Annual Meeting this past weekend. The French company also shared developmental updates from the 470 Mont Blanc phase 3 clinica
- Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinkinghttps://modernod.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. “Op
- Study Demonstrates Efficacy of AI in Enabling Home OCT Monitoringhttps://modernod.com/news/study-demonstrates-efficacy-of-ai-in-enabling-home-oct-monitoring/2482641/Notal Vision announced the publication of pivotal study results evaluating the performance of its artificial intelligence (AI) algorithm designed to estimate key biomarkers in wet age-
- MERIT Acquires OSOD to Expand Ophthalmic Drug Development Serviceshttps://modernod.com/news/merit-acquires-osod-to-expand-ophthalmic-drug-development-services/2482629/MERIT announced its has acquired OSOD, which assists with ophthalmic preclinical drug development. The acquisition enhances MERIT’s capabilities, enabling a transition from preclinical to clinical phases of drug development. Accordin
- Nacuity Pharmaceuticals Granted FDA Fast Track Designation for NPI-001 Tablets for RPhttps://modernod.com/news/nacuity-pharmaceuticals-granted-fda-fast-track-designation-for-npi-001-tablets-for-retinitis-pigmentosa/2482625/Nacuity Pharmaceuticals announced that the FDA has granted Fast Track Designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy for the treatment of patients with retinitis pigmentosa (RP). A drug may receive Fast Track designation
- Bausch + Lomb Makes Two Deals to Bolster Therapeutic Pipeline in GA and Glaucomahttps://modernod.com/news/bausch-lomb-makes-two-deals-to-bolster-therapeutic-pipeline-in-ga-and-glaucoma/2482612/Bausch + Lomb announced two separate deals to acquire early- and mid-stage therapeutic assets. First, B+L, through an affiliate, acquired Whitecap Biosciences LLC, which is developing two therapies for potential use in glaucoma and geographic atrophy (GA). Financial terms
- Dry Eye Institute Launches 'DEI On Demand' and Kicks Off Inaugural Road Eventhttps://modernod.com/news/dry-eye-institute-launches-dei-on-demand-and-kicks-off-inaugural-road-event/2482605/The Dry Eye Institute (DEI), an educational program for optometrists and ophthalmologists specializing in advanced dry eye care, has announced that for the first time, the institute’s curriculum is now available online through 'DEI On Demand.' DEI also announced that
- ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901; DSMB Approval to Advance Dose Escalation in Phase 1b RP Trialhttps://modernod.com/news/vigeneron-announces-fda-rare-pediatric-disease-designation-for-vg901-dsmb-approval-to-advance-dose-escalation-in-phase-1b-rp-trial/2482601/ViGeneron announced two important milestones for its novel gene therapy candidate VG901 to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The FDA granted Rare Pediatric Disease Designation (RPD
- National Eye Institute Study Revisits Role of Annexin-V Biomarker in Retinal Cell Degenerationhttps://modernod.com/news/national-eye-institute-study-revisits-role-of-annexin-v-biomarker-in-retinal-cell-degeneration/2482588/Recent findings from a National Eye Institute-led study shed new light on annexin-V, a widely used biomarker to track apoptosis and retinal cell death in eye disease. The study group identified that annexin-V also binds to immune cells, suggesting it may a have a role as a marker for ocular infla